Innovative Treatments and Technologies
The Stanford team is commonly involved in testing new cancer treatments not yet available at other facilities. Examples include:
- Targeted therapies that attack tumor surface proteins, aberrant epigenetic regulation, signaling or cell survival pathways, or microenvironment
- Mogamulizumab (KW-0761) is a bioengineered, humanized monoclonal antibody against CCR4, selectively expressed on tumor cells; the defucosylated technology provides enhanced efficacy
- Brentuximab vedotin (SGN-35) is an antibody-drug-conjugate that targets CD30, commonly expressed on tumor cells in cutaneous T-cell lymphomas
- Low-dose (12 Gy) total skin electron beam therapy combined with vorinostat, a potentially radiation enhancing agent, to reduce overall toxicity of radiation while improving efficacy
- Pralatrexate, as newer anti-folate agent, combined with oral bexarotene demonstrates synergistic efficacy
- Novel/newer topical agents including topical histone deacetylase inhibitor
- Non-myeloablative allogeneic hematopoietic stem cell transplantation using total skin electron beam therapy, total lymphoid irradiation, and anti-thymocyte globulin as novel preparatory regimen for patients with mycosis fungoides and Sezary syndrome
- Newer techniques utilizing rapid molecular diagnostic methods or new immunostains for earlier and more accurate diagnosis
Stanford multispecialty care
The Stanford Multspecialty Cutaneous Lymphoma Clinic (MCLC) is a national leader in clinical/translational research and treatment of patients with cutaneous lymphomas. In operation for over 30 years at Stanford, the MCLC (similar to a tumor board) is held twice weekly and patients are co-evaluated and co-managed by cutaneous, medical, and radiation oncologists, and pathologists who each have expertise in cutaneous lymphoma. Stanford is unique in offering this interdisciplinary care in cutaneous lymphoma to provide the most comprehensive and optimal care for patients with this very rare group of lymphomas.
